Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-833/OBI-821 with First-Line Erlotinib in EGFR-Mutated NSCLC
NCT05442060Phase 2Recruiting
- Sponsor
- OBI Pharma
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of OBI-833 in non-small cell lung cancer (NSCLC), sponsored by OBI Pharma. Started Jul 2022; status: recruiting.
02
Drugs
OBI-833
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05442060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442060.